Abstract Severe coronavirus disease 2019 (COVID-19) is characterized by systemic hyper-
inflammation, acute respiratory distress syndrome, and multiple organ failure. Cytokine …

The world has faced the most challenging pandemic of the modern era, that of severe acute
respiratory syndrome coronavirus 2 infection, causing coronavirus disease and affecting …

Introduction The most serious COVID‐19 deriving from severe acute respiratory syndrome
coronavirus 2 causes a cytokine release storm and it is associated with worse outcomes. In …

For the initial phase of pandemic of coronavirus disease 2019 (COVID-19), repurposing
drugs that in vitro inhibit severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) …

At present, healthcare systems all over the world are coping with the new coronavirus
infection [1]. In particular, tremendous efforts are are being made in order to support …

Background Cancer and transplant patients with COVID-19 have a higher risk of developing
severe and even fatal respiratory diseases, especially as they may be treated with immune …

Summary Coronavirus disease 2019 (COVID‐19) is a clinical syndrome caused by the
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus. Patients can be …

After analyzing the immune characteristics of patients with severe coronavirus disease 2019
(COVID-19), we have identified that pathogenic T cells and inflammatory monocytes with …

SARS-Corona-Virus-2 related disease (COVID-19) which started in Wuhan, China on
December 2019, is spreading rapidly throughout the world [1]. COVID-19 clinical spectrum is …

Since the beginning of the pandemic, numerous national and international clinical trials
have been conducted with a large number of drugs. Many of them are intended for the …